Mofegiline

Source: Wikipedia, the free encyclopedia.
Mofegiline
Clinical data
Other namesMDL-72,974A
Routes of
administration		Oral[1]
ATC code
  • None
Legal status
Legal status
  • Development terminated
Pharmacokinetic data
Elimination half-life1–3 hours[1]
ExcretionUrine[2]
Identifiers
  • (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine
JSmol)
  • Fc1ccc(cc1)CCC(=[C@H]F)CN
  • InChI=1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+
  • Key:VXLBSYHAEKDUSU-JXMROGBWSA-N

Mofegiline (MDL-72,974) is a

semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease,[3][4][5][6] but was never marketed.[7]

See also

References

  1. ^
    S2CID 21543441
    .
  2. PMID 8489556
    .
  3. S2CID 32734728
    .
  4. S2CID 26335432
    .
  5. PMID 7931257
    .
  6. S2CID 20976168
    .
  7. ISBN 978-0-412-46630-4
    . Retrieved 25 November 2011.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mofegiline&oldid=1203436088"